Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19 is a research paper published in JCI Insight (2022). On theSindex it has a DataRank of 0. It has been cited 21 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: UM1 AI068618,UM1 AI068635,UM1 AI068614,UM1 AI148452,P30 AI045008,P30 AI064518,T32 AI141342
Bill and Melinda Gates Foundation
Grant: INV008612
NIAID NIH HHS
Grant: UM1 AI069534
NIAID NIH HHS
Grant: U01 AI068614
NIAID NIH HHS
Grant: P30 AI064518
NIAID NIH HHS
Grant: UM1 AI148452
NIAID NIH HHS
Grant: UM1 AI068618
NIAID NIH HHS
Grant: U01 AI068618
NIAID NIH HHS
Grant: T32 AI141342
NIAID NIH HHS
Grant: UM1 AI068635
NIAID NIH HHS
Grant: P30 AI045008
NIAID NIH HHS
Grant: U01 AI068635
National Institutes of Health
Grant: 2T32AI141342-06
Advanced Immunobiology Traning Program for Surgeons
National Institutes of Health
Grant: 5UM1AI148452-02
Vanderbilt Vaccine and Treatment Evaluation Unit
National Institutes of Health
Grant: 5P30AI064518-17
Centers for AIDS Research (CFAR)
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 5P30AI045008-10
Core--Immunology Facility
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
FWCI
1.45
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals